Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT323 and BNT327 in Advanced Breast Cancer
NCT06827236Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Apr 2025
- Primary completion
- Aug 2029
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of trastuzumab pamirtecan, pumitamig in breast cancer, sponsored by BioNTech SE. Started Apr 2025; status: recruiting.
02
Drugs
trastuzumab pamirtecanpumitamig
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06827236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827236.